Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
117 studies found for:    johnstown
Show Display Options
Rank Status Study
1 Active, not recruiting Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Oligodendroglioma;   Recurrent Adult Brain Neoplasm
Interventions: Biological: Bevacizumab;   Biological: Trebananib;   Other: Placebo;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
2 Recruiting Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Adenocarcinoma;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
Interventions: Radiation: Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
3 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Biological: Pertuzumab;   Drug: Goserelin Acetate;   Procedure: Therapeutic Conventional Surgery;   Radiation: Whole Breast Irradiation;   Other: Laboratory Biomarker Analysis;   Drug: Aromatase Inhibition Therapy;   Other: Quality-of-Life Assessment
4 Active, not recruiting Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Condition: Breast Cancer
Interventions: Radiation: Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy;   Radiation: Higher per daily radiation therapy;   Radiation: Concurrent boost radiotherapy;   Radiation: Standard per daily radiation therapy;   Radiation: Sequential boost radiotherapy
5 Recruiting Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Condition: Ductal Breast Carcinoma In Situ
Interventions: Biological: Trastuzumab;   Radiation: Whole Breast Irradiation;   Other: Laboratory Biomarker Analysis
6 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
Interventions: Drug: Ibrutinib;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Biological: Rituximab;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
7 Completed
Has Results
Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer
Conditions: Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Biological: bevacizumab;   Drug: cisplatin;   Drug: fluorouracil
8 Recruiting Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
Condition: Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Radiation: Intensity-Modulated Radiation Therapy
9 Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
10 Active, not recruiting Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Cognitive/Functional Effects
Interventions: Drug: temozolomide;   Biological: bevacizumab;   Other: placebo;   Radiation: intensity-modulated radiation therapy;   Radiation: 3-dimensional conformal radiation therapy;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis;   Procedure: dynamic susceptibility contrast-enhanced magnetic resonance imaging;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
11 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
12 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
13 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
14 Active, not recruiting Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Bendamustine;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin;   Drug: Prophylaxis;   Drug: Antibiotic;   Other: Biweekly Follow Up;   Other: Cyclical Follow Up;   Other: Restaging;   Other: Post-Treatment Follow Up
15 Withdrawn Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Conditions: Adenoma, Pleomorphic;   Mixed Salivary Gland Tumor;   Salivary Gland Tumor, Mixed;   Syringoma, Chondroid
Interventions: Radiation: Radiation;   Drug: Panitumumab
16 Completed
Has Results
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Intervention: Drug: RAD001 (everolimus)
17 Completed Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: doxorubicin and bortezomib
18 Completed Comparative Study Between Continuous Epidural Anesthesia And Continuous Spinal Anesthesia Using Wiley™ Spinal Catheter
Condition: Anesthesia; Adverse Effect, Spinal and Epidural
Interventions: Device: Epidural (B. Braun);   Device: Spinal (Wiley Spinal Catheter)
19 Completed A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
Condition: Postherpetic Neuralgia
Interventions: Drug: pregabalin;   Drug: pregabalin/PF-00489791;   Drug: Placebo
20 Unknown  An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain
Condition: Pain, Postoperative
Intervention: Drug: DIC075V  (intravenous diclofenac sodium)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years